インスリンデリバリーデバイスの世界市場：洞察、競合情勢、市場予測：2030年

世界のインスリンデリバリーデバイスの市場規模は、2023年に155億1,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に9.28％のCAGRで拡大し、2030年には263億5,000万米ドルに達すると予測されています。インスリンデリバリーデバイスの需要増加は、老年人口の糖尿病有病率の上昇、有利な償還シナリオ、適切な糖尿病管理とインスリンデリバリーデバイスに関する認知度の上昇、製品ラインの技術的進歩などが主な要因です。

世界のインスリンデリバリーデバイス市場を拡大させる主な要因は、大衆の間での糖尿病有病率の上昇です。糖尿病は、体が生成されたインスリンを効果的に使用できないか、または膵臓が十分なインスリンを生成しない場合に発生する慢性的な状態です。IDF Diabetes Atlas（2023）の統計によると、2021年には5億3,700万人の成人が糖尿病を患っていました。この数は2030年には6億4,300万人、2045年には7億8,300万人に増加すると予測されています。

肥満が糖尿病リスクを高める傾向があるため、成人・小児を含む世界中の過体重・肥満人口の増加が、インスリンデリバリーデバイスの市場成長を後押しすると予測されています。世界肥満連盟（World Obesity Federation 2022）によると、2030年までに世界中の約10億人（女性の5人に1人、男性の7人に1人）が肥満と共存すると予測されています。世界保健機関（WHO）2021によると、2020年には全世界で5歳以下の約3,900万人の子供が過体重または肥満でした。

当レポートでは、世界のインスリンデリバリーデバイス市場について調査し、市場の概要とともに、製品タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 インスリンデリバリーデバイス市場レポートのイントロダクション

第2章 インスリンデリバリーデバイス市場のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 インスリンデリバリーデバイス市場の主な要因分析

• インスリンデリバリーデバイス市場の促進要因
• インスリンデリバリーデバイス市場の抑制要因と課題
• インスリンデリバリーデバイス市場の機会

第5章 インスリンデリバリーデバイスにおけるポーターのファイブフォース分析

第6章 インスリンデリバリーデバイス市場の概要

• 製品タイプ別
• エンドユーザー別
• 地域別

第7章 インスリンデリバリーデバイスの企業と製品プロファイル

• Medtronic
• Abbott
• BD
• Terumo
• YPSOMED
• Tandem Diabetes Care, Inc.
• Novo Nordisk A/S
• Biocon Ltd.
• Insulet Corporation
• Eli Lilly and Company
• CeQur
• EOFLOW CO., LTD.
• European Pharma Group BV
• Roche
• Sanofi
• Hindustan Syringes & Medical Devices Ltd
• Ocean (Hangzhou) Medical Technology Co Ltd.
• Owen Mumford
• SOOIL Developments Co., Ltd
• SUNGSHIM MEDICAL CO., LTD.

第8章 KOL の見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightのサービス内容

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Insulin Delivery Devices Market in Global (2021-2030)
• Table 3: Insulin Delivery Devices Market in Global by Product Type (2021-2030)
• Table 4: Insulin Delivery Devices Market in Global by End-User (2021-2030)
• Table 5: Insulin Delivery Devices Market in Global by Geography (2021-2030)
• Table 6: Insulin Delivery Devices Market in North America (2021-2030)
• Table 7: Insulin Delivery Devices Market in the US (2021-2030)
• Table 8: Insulin Delivery Devices Market in Canada (2021-2030)
• Table 9: Insulin Delivery Devices Market in Mexico (2021-2030)
• Table 10: Insulin Delivery Devices Market in Europe (2021-2030)
• Table 11: Insulin Delivery Devices Market in France (2021-2030)
• Table 12: Insulin Delivery Devices Market in Germany (2021-2030)
• Table 13: Insulin Delivery Devices Market in the United Kingdom (2021-2030)
• Table 14: Insulin Delivery Devices Market in Italy (2021-2030)
• Table 15: Insulin Delivery Devices Market in Spain (2021-2030)
• Table 16: Insulin Delivery Devices Market in Rest of Europe (2021-2030)
• Table 17: Insulin Delivery Devices Market in Asia-Pacific (2021-2030)
• Table 18: Insulin Delivery Devices Market in China (2021-2030)
• Table 19: Insulin Delivery Devices Market in Japan (2021-2030)
• Table 20: Insulin Delivery Devices Market in India (2021-2030)
• Table 21: Insulin Delivery Devices Market in Australia (2021-2030)
• Table 22: Insulin Delivery Devices Market in South Korea (2021-2030)
• Table 23: Insulin Delivery Devices Market in Rest of Asia-Pacific (2021-2030)
• Table 24: Insulin Delivery Devices Market in the Rest of the World (2021-2030)
• Table 25: Insulin Delivery Devices Market in the Middle East (2021-2030)
• Table 26: Insulin Delivery Devices Market in Africa (2021-2030)
• Table 27: Insulin Delivery Devices Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Insulin Delivery Devices Market in Global (2021-2030)
• Figure 3: Insulin Delivery Devices Market in Global by Product Type (2021-2030)
• Figure 4: Insulin Delivery Devices Market in Global by End-User (2021-2030)
• Figure 5: Insulin Delivery Devices Market in Global by Geography (2021-2030)
• Figure 6: Insulin Delivery Devices Market in North America (2021-2030)
• Figure 7: Insulin Delivery Devices Market in the US (2021-2030)
• Figure 8: Insulin Delivery Devices Market in Canada (2021-2030)
• Figure 9: Insulin Delivery Devices Market in Mexico (2021-2030)
• Figure 10: Insulin Delivery Devices Market in Europe (2021-2030)
• Figure 11: Insulin Delivery Devices Market in France (2021-2030)
• Figure 12: Insulin Delivery Devices Market in Germany (2021-2030)
• Figure 13: Insulin Delivery Devices Market in the United Kingdom (2021-2030)
• Figure 14: Insulin Delivery Devices Market in Italy (2021-2030)
• Figure 15: Insulin Delivery Devices Market in Spain (2021-2030)
• Figure 16: Insulin Delivery Devices Market in Rest of Europe (2021-2030)
• Figure 17: Insulin Delivery Devices Market in Asia-Pacific (2021-2030)
• Figure 18: Insulin Delivery Devices Market in China (2021-2030)
• Figure 19: Insulin Delivery Devices Market in Japan (2021-2030)
• Figure 20: Insulin Delivery Devices Market in India (2021-2030)
• Figure 21: Insulin Delivery Devices Market in Australia (2021-2030)
• Figure 22: Insulin Delivery Devices Market in South Korea (2021-2030)
• Figure 23: Insulin Delivery Devices Market in Rest of Asia-Pacific (2021-2030)
• Figure 24: Insulin Delivery Devices Market in the Rest of World (2021-2030)
• Figure 25: Insulin Delivery Devices Market in the Middle East (2021-2030)
• Figure 26: Insulin Delivery Devices Market in Africa (2021-2030)
• Figure 27: Insulin Delivery Devices Market in South America (2021-2030)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Market Opportunities
• Figure 31: PORTER's Five Force Analysis

Insulin Delivery Devices Market By Product Type (Insulin Syringes, Insulin Pens, Insulin Pumps [Tethered/External Pumps and Patch Pumps], Insulin Injectors, and Others), End-User (Homecare Settings, Diabetes Centers, Hospitals, and Others), and Geography is anticipated to expand at a significant CAGR forecast till 2030 due to rising prevalence of diabetes across the globe and rising awareness regarding proper diabetes management among patients

The global insulin delivery devices market was valued at USD 15.51 billion in 2023, growing at a CAGR of 9.28% during the forecast period from 2024 to 2030, to reach USD 26.35 billion by 2030. The rise in demand for insulin delivery devices is predominantly attributed to the rising prevalence of diabetes among the geriatric population, favorable reimbursement scenarios, rising awareness about proper diabetes management and insulin delivery devices, and technological advancement in the product line, among others.

Insulin Delivery Devices Market Dynamics:

The factor which plays a major role in increasing the global insulin delivery device market is the rising prevalence of diabetes among the masses. Diabetes is a chronic condition that occurs either when the body cannot use the insulin produced effectively or when the pancreas does not produce enough insulin. As per statistics by the IDF Diabetes Atlas (2023), 537 million adults were living with diabetes in 2021. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.

The increasing number of overweight and obese people across the globe including adults and children is anticipated to bolster the market growth for insulin delivery devices as obesity tends to increase the risk for diabetes. According to the World Obesity Federation 2022, it has been predicted that by 2030 about 1 billion people around the world, including 1 in 5 women and 1 in 7 men, will be living with obesity. As per the World Health Organization 2021, worldwide about 39 million children aged below 5 years were overweight or obese in 2020.

In addition, the development and approval of advanced insulin delivery devices for the treatment of type I diabetes which has an incidence of 15 per 100,000 people and a prevalence of 9.5% in the world as per various research studies, is also projected to fuel the global insulin delivery devices market. For instance, in 2020, the US Food and Drug Administration (FDA) approved the MiniMed 770G System, a hybrid closed-loop diabetes management device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses with little or no input from the users or their caregivers for use by individuals aged 2 to 6 with type 1 diabetes.

Certain factors such as the availability of oral insulin medications and the high cost of insulin delivery devices are likely to impede the insulin delivery devices market growth.

Insulin Delivery Devices Market Segment Analysis:

Insulin Delivery Devices Market By Product Type (Insulin Syringes, Insulin Pens, Insulin Pumps [Tethered/External Pumps and Patch Pumps], Insulin Injectors, and Others), End-User (Homecare Settings, Diabetes Centres, Hospitals, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the insulin delivery devices product segment, insulin pens are projected to hold the largest market among other insulin delivery devices. This is due to the ease of use of the insulin pen and its flexibility to incorporate insulin injections into a busy lifestyle which improves diabetes control with less effort while maintaining the quality of life for diabetic patients. Various other factors such as user-friendly design, rising popularity, and adoption rate among the patient population are also anticipated to contribute to the segmental growth of the insulin delivery devices market.

Moreover, the rising focus of manufacturers on developing smart insulin pens integrated with real-time continuous glucose monitoring data to provide efficient diabetes management for patients is likely to boost the segmental market. For instance, in 2020, Medtronic launched InPen(TM) integrated with real-time Guardian Connect(TM) CGM data which is the first and only FDA-cleared smart insulin pen on the market for people on multiple daily injections (MDI).

Thereby, the aforementioned factors are expected to accelerate the demand for insulin pens during the forecast period.

North America is expected to dominate the overall Insulin Delivery Devices Market:

Among all the countries, North America is expected to dominate the overall insulin delivery devices market during the forecast period. this domination is due to the increase in venture capital for the issuance of initial public offerings, favorable reimbursement policies, and the presence of improved healthcare infrastructure in the region.

Further, the rising prevalence of diabetes among the population in the US is also likely to fuel the insulin delivery devices market in the region. For instance, according to National Diabetes Statistics Report, 2020, 34.2 million Americans have diabetes, and newly diagnosed cases of type 1 and type 2 diabetes have significantly increased among US youth.

In addition, the presence of key manufacturers such as Medtronic, Becton, Dickinson and Company, and Tandem Diabetes Care, Inc., among others is also a driving factor for the regional growth of the insulin delivery devices market.

Furthermore, recent commercialization activities among the key manufacturers in the region also contribute to the growth of the insulin delivery devices market in the region. For instance, in June 2020, Abbott and Tandem Diabetes Care agreed to develop and commercialize integrated diabetes solutions that combine Abbott's continuous glucose monitoring (CGM) technology with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.

Insulin Delivery Devices Market Key Players:

Some of the key market players operating in the Insulin Delivery Devices market include Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and others.

Recent Developmental Activities in the Insulin Delivery Devices Market:

In November 2020, the French company Diabeloop, a pioneer in therapeutic AI, and Terumo Corporation signed an agreement for the joint development with exclusive distribution rights in Japan of an automated insulin delivery (AID) solution. The Diabeloop-developed system will integrate Terumo's innovative insulin patch pump.

In June 2020, Medtronic received CE (Conformite Europeenne) Marking for its MiniMed(TM) 780G system, a next-generation closed-loop insulin pump system for the treatment of type 1 diabetes in people aged 7 to 80 years.

In February 2020, Abbott and Insulet Corporation entered into a partnership agreement to integrate Abbott's glucose-sensing technology with Insulet's next-generation tubeless system, the Omnipod Horizon(TM) Automated Insulin Delivery (AID) System (Omnipod Horizon System), to offer personalized automated insulin delivery and care for people living with diabetes.

Key Takeaway from the Insulin Delivery Devices Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global insulin delivery devices market.

Various opportunities available for the other competitor in the insulin delivery devices market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for insulin delivery devices market growth in the coming future?

Target Audience who can be benefited from the Insulin Delivery Devices Market Report Study

Insulin Delivery Devices providers

Research organizations and consulting companies

Insulin Delivery Devices-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Insulin Delivery Devices

Various End-Users who want to know more about the insulin delivery devices market and the latest technological developments in the insulin delivery devices market.

Frequently Asked Questions for Insulin Delivery Devices Market:

1. What are Insulin Delivery Devices?

Insulin delivery devices are used to inject insulin into the body. There are different types of insulin delivery devices available comprising syringes, pens, jet injectors, insulin pumps, among others.

2. What is the market for Global Insulin Delivery Devices?

The global Insulin Delivery Devices Market was valued at USD 15.51 billion in 2023, growing at a CAGR of 9.28% during the forecast period from 2024 to 2030, to reach USD 26.35 billion by 2030.

3. What are the drivers for Global Insulin Delivery Devices?

The major factors driving the demand for insulin delivery devices are the rising prevalence of diabetes among the worldwide population, increasing focus on developing advanced insulin delivery systems, and rising awareness regarding proper diabetes management, among others.

4. Who are the key players operating in the global insulin delivery devices market?

Some of the key market players operating in the insulin delivery devices market include Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD. and others.

5. Which region has the highest share in the insulin delivery devices market?

North America is expected to dominate the overall insulin delivery devices market during the forecast period, 2024 to 2030 due to the presence of giant market players in the region, improved healthcare infrastructure, the growing burden of diabetes patients, and various recent product developmental activities by the medical device companies, among others.

Table of Contents

1. Insulin Delivery Devices Market Report Introduction

2. Insulin Delivery Devices Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Insulin Delivery Devices Market Key Factors Analysis

• 4.1. Insulin Delivery Devices Market Drivers
  • 4.1.1. Rising prevalence of diabetes
  • 4.1.2. Favorable reimbursement
  • 4.1.3. Increasing technological advancement
  • 4.1.4. Rising awareness about proper diabetes management and insulin delivery devices
• 4.2. Insulin Delivery Devices Market Restraints and Challenges
  • 4.2.1. Availability of oral medications
  • 4.2.2. High cost of the insulin delivery devices
• 4.3. Insulin Delivery Devices Market Opportunities
  • 4.3.1. The shift toward advanced closed-loop insulin delivery systems
  • 4.3.2. Rising healthcare expenditure in the emerging nation offers Opportunities

5. Insulin Delivery Devices Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. Insulin Delivery Devices Market Layout

• 6.1. By Product Type
  • 6.1.1. Insulin Syringes
  • 6.1.2. Insulin pens
  • 6.1.3. Insulin Pumps
    • 6.1.3.1. External/Tethered Pumps
    • 6.1.3.2. Patch Pumps
  • 6.1.4. Insulin Injectors
  • 6.1.5. Others
• 6.2. By End-User
  • 6.2.1. Hospitals
  • 6.2.2. Ambulatory Surgical Centers
  • 6.2.3. Others
• 6.3. By Geography
  • 6.3.1. North America Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.1.1. United States Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.1.2. Canada Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.1.3. Mexico Insulin Delivery Devices Market Size in USD million (2021-2030)
  • 6.3.2. Europe Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.2.1. France Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.2.2. Germany Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.2.3. United Kingdom Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.2.4. Italy Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.2.5. Spain Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.2.6. Rest of Europe Insulin Delivery Devices Market Size in USD million (2021-2030)
  • 6.3.3. Asia-Pacific Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.3.1. China Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.3.2. Japan Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.3.3. India Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.3.4. Australia Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.3.5. South Korea Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.3.6. Rest of Asia-Pacific Insulin Delivery Devices Market Size in USD million (2021-2030)
  • 6.3.4. Rest of the World (RoW) Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.4.1. Middle East Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.4.2. Africa Insulin Delivery Devices Market Size in USD million (2021-2030)
    • 6.3.4.3. South America Insulin Delivery Devices Market Size in USD million (2021-2030)

7. Insulin Delivery Devices Company and Product Profiles

• 7.1. Medtronic
  • 7.1.1. Company Overview
  • 7.1.2. Company Snapshot
  • 7.1.3. Financial Overview
  • 7.1.4. Product Listing
  • 7.1.5. Entropy
• 7.2. Abbott
  • 7.2.1. Company Overview
  • 7.2.2. Company Snapshot
  • 7.2.3. Financial Overview
  • 7.2.4. Product Listing
  • 7.2.5. Entropy
• 7.3. BD
  • 7.3.1. Company Overview
  • 7.3.2. Company Snapshot
  • 7.3.3. Financial Overview
  • 7.3.4. Product Listing
  • 7.3.5. Entropy
• 7.4. Terumo
  • 7.4.1. Company Overview
  • 7.4.2. Company Snapshot
  • 7.4.3. Financial Overview
  • 7.4.4. Product Listing
  • 7.4.5. Entropy
• 7.5. YPSOMED
  • 7.5.1. Company Overview
  • 7.5.2. Company Snapshot
  • 7.5.3. Financial Overview
  • 7.5.4. Product Listing
  • 7.5.5. Entropy
• 7.6. Tandem Diabetes Care, Inc.
  • 7.6.1. Company Overview
  • 7.6.2. Company Snapshot
  • 7.6.3. Financial Overview
  • 7.6.4. Product Listing
  • 7.6.5. Entropy
• 7.7. Novo Nordisk A/S
  • 7.7.1. Company Overview
  • 7.7.2. Company Snapshot
  • 7.7.3. Financial Overview
  • 7.7.4. Product Listing
  • 7.7.5. Entropy
• 7.8. Biocon Ltd.
  • 7.8.1. Company Overview
  • 7.8.2. Company Snapshot
  • 7.8.3. Financial Overview
  • 7.8.4. Product Listing
  • 7.8.5. Entropy
• 7.9. Insulet Corporation
  • 7.9.1. Company Overview
  • 7.9.2. Company Snapshot
  • 7.9.3. Financial Overview
  • 7.9.4. Product Listing
  • 7.9.5. Entropy
• 7.10. Eli Lilly and Company
  • 7.10.1. Company Overview
  • 7.10.2. Company Snapshot
  • 7.10.3. Financial Overview
  • 7.10.4. Product Listing
  • 7.10.5. Entropy
• 7.11. CeQur
  • 7.11.1. Company Overview
  • 7.11.2. Company Snapshot
  • 7.11.3. Financial Overview
  • 7.11.4. Product Listing
  • 7.11.5. Entropy
• 7.12. EOFLOW CO., LTD.
  • 7.12.1. Company Overview
  • 7.12.2. Company Snapshot
  • 7.12.3. Financial Overview
  • 7.12.4. Product Listing
  • 7.12.5. Entropy
• 7.13. European Pharma Group BV
  • 7.13.1. Company Overview
  • 7.13.2. Company Snapshot
  • 7.13.3. Financial Overview
  • 7.13.4. Product Listing
  • 7.13.5. Entropy
• 7.14. Roche
  • 7.14.1. Company Overview
  • 7.14.2. Company Snapshot
  • 7.14.3. Financial Overview
  • 7.14.4. Product Listing
  • 7.14.5. Entropy
• 7.15. Sanofi
  • 7.15.1. Company Overview
  • 7.15.2. Company Snapshot
  • 7.15.3. Financial Overview
  • 7.15.4. Product Listing
  • 7.15.5. Entropy
• 7.16. Hindustan Syringes & Medical Devices Ltd
  • 7.16.1. Company Overview
  • 7.16.2. Company Snapshot
  • 7.16.3. Financial Overview
  • 7.16.4. Product Listing
  • 7.16.5. Entropy
• 7.17. Ocean (Hangzhou) Medical Technology Co Ltd.
  • 7.17.1. Company Overview
  • 7.17.2. Company Snapshot
  • 7.17.3. Financial Overview
  • 7.17.4. Product Listing
  • 7.17.5. Entropy
• 7.18. Owen Mumford
  • 7.18.1. Company Overview
  • 7.18.2. Company Snapshot
  • 7.18.3. Financial Overview
  • 7.18.4. Product Listing
  • 7.18.5. Entropy
• 7.19. SOOIL Developments Co., Ltd
  • 7.19.1. Company Overview
  • 7.19.2. Company Snapshot
  • 7.19.3. Financial Overview
  • 7.19.4. Product Listing
  • 7.19.5. Entropy
• 7.20. SUNGSHIM MEDICAL CO., LTD.
  • 7.20.1. Company Overview
  • 7.20.2. Company Snapshot
  • 7.20.3. Financial Overview
  • 7.20.4. Product Listing
  • 7.20.5. Entropy

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us